検索対象:     
報告書番号:
※ 半角英数字
 年 ~ 
 年

Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for $$alpha$$ radionuclide therapy

$$alpha$$線標的治療のためのアスタチン-211標識シグマ受容体リガンドの合成と評価

小川 数馬*; 水野 覚瑛*; 鷲山 幸信*; 柴 和弘*; 高橋 成人*; 小阪 孝史*; 渡辺 茂樹; 篠原 厚*; 小谷 明*

Ogawa, Kazuma*; Mizuno, Yoshiaki*; Washiyama, Koshin*; Shiba, Kazuhiro*; Takahashi, Naruto*; Kozaka, Takashi*; Watanabe, Shigeki; Shinohara, Atsushi*; Odani, Akira*

Sigma receptors are overexpressed in a variety of human tumors, making them potential targets for radionuclide receptor therapy. We have previously synthesized and evaluated $$^{131}$$I-labeled (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-[$$^{131}$$I]pIV], which has a high affinity for sigma receptors. Therefore, (+)-[$$^{131}$$I]pIV significantly inhibited tumor cell proliferation in tumor-bearing mice. In the present study, we report the synthesis and the in vitro and in vivo characterization of (+)-[$$^{211}$$At]pAtV, an $$^{211}$$At-labeled sigma receptor ligand, that has potential use in $$alpha$$-radionuclide receptor therapy. The lipophilicity of (+)-[$$^{211}$$At]pAtV was similar to that of (+)-[$$^{125}$$I]-pIV. Uptake of DU-145, prostate cancer cell lines, and the biodistribution patterns in DU-145 tumor-bearing mice at 1 h post-injection were also similar between (+)-[$$^{211}$$At]pAtV and (+)-[$$^{125}$$I]-pIV. Namely, (+)-[$$^{211}$$At]pAtV demonstrated high uptake and retention in tumor via binding to sigma receptors.

Access

:

- Accesses

InCites™

:

パーセンタイル:71.75

分野:Radiology, Nuclear Medicine & Medical Imaging

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.